Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

导出原文传递

翻译打印收藏纠错

作者： Hironori,Uruga ^[1] ; Emine,Bozkurtlar ^[1] ; Tiffany G,Huynh ^[1] ; Alona,Muzikansky ^[2] ; Yasushi,Goto ^[3] ; Maria,Gomez-Caraballo ^[2] ; Aaron N,Hata ^[4] ; Justin F,Gainor ^[4] ; Eugene J,Mark ^[5] ; Jeffrey A,Engelman ^[4] ; Michael D,Lanuti ^[6] ; Mari,Mino-Kenudson ^[7]

作者单位： Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. ^[1] Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. ^[2] Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[3] Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. ^[4] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. ^[5] Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts. ^[6] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address: MMINOKENUDSON@partners.org. ^[7]

关键词 Adjuvant therapy Lung adenocarcinoma Lymph node metastasis PD-L1 Programmed death-ligand 1 Tumor-infiltrating lymphocyte